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IV Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2
Palavras-chave:
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Imunofluorescência indireta
Consenso de FAN-HEp-2
r e s u m o
Objetivo: O IV Consenso Brasileiro para Pesquisa de Autoanticorpos em Células HEp-2 (FAN) 
realizado em Vitória (ES), no dia 18 de setembro de 2012, objetivou discutir estratégias e 
recomendações relacionadas ao procedimento técnico, à padronização e à interpretação 
dos resultados da pesquisa de autoanticorpos em células HEp-2. 
Métodos: Participaram do evento 23 pesquisadores e especialistas de Universidades e labo-
ratórios brasileiros. Foram abordados diferentes tópicos, discutidos amplamente a fim de 
se estabelecer recomendações específicas. 
Resultados e conclusão: O IV Consenso integrou à árvore de decisão o padrão citoplas-
mático em Anéis e Bastões, o padrão nuclear pontilhado Quasi-homogêneo (QH) e o 
padrão misto CENP-F. Discutiu-se ainda a necessidade de atenção para a classificação 
do padrão misto relacionado à presença de anticorpos anti-DNA topoisomerase I (Scl-
70), compreendendo os componentes nuclear pontilhado fino, nucleolar homogêneo, 
NOR na placa metafásica e citoplasmático pontilhado fino. Foram sugeridas diretrizes 
para o controle de qualidade do teste, diluição de triagem e diluição de esgotamento, 
e foi emitido alerta quanto à necessidade de atenção em relação à heterogeneidade de 
substratos disponíveis no mercado e a utilização de metodologias automatizadas para 
detecção de autoanticorpos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Objective: The Fourth Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells 
(ANA) was held in Vitória, Espírito Santo, and aimed to discuss strategies and recommen-
dations about the technique, standardization, interpretation and quality control of the in-
direct immunofluorescence reaction on HEp-2 cells.
Methods: Twenty three ANA experts from university centers and private laboratories in dif-
ferent areas from Brazil discussed and agreed upon recommendations for the fourth edi-
tion of the Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells.
Results and conclusion: The 4th ANA Consensus included three novel patterns into the ex-
isting algorithm (cytoplasmic Rods and Rings, nuclear Quasi-homogeneous, and CENP-F). 
Emphasis was given to the need of attention in describing the peculiar mixed pattern elic-
ited by anti-DNA topoisomerase I (Scl-70) autoantibodies, comprising nuclear fine specked, 
nucleolar homogeneous pattern, NOR staining in metaphase plates, and cytoplasmic fine 
speckled patterns. The group also emphasized the need for continuous quality control in 
indirect immunofluorescence assays, the establishment of screening dilutions, as well as 
conjugate titration. An alert was made regarding the heterogeneity of commercial kits in 
defining patterns and the use of solid phase methodologies to determine the presence of 
autoantibodies. 
© 2014 Elsevier Editora Ltda. All rights reserved.
Introduction
Over the last decade, the evaluation of autoantibodies 
against cellular antigens by indirect immunofluorescence 
(IIF) on HEp-2 cells underwent elaborate process of national 
standardization. These actions began in 2000, bringing sev-
eral repercussions in Brazilian territory for the completion 
and interpretation of the test,1-4 stimulating even similar in-
ternational initiatives.5-8
The first Consensuses were aimed at establishing of ac-
tions in order to standardizing criteria for reading and in-
terpreting the different patterns of autoantibodies on HEp-2 
cells. Classification algorithms, based on morphological cri-
teria and establishing five main groups of patterns (nuclear, 
nucleolar, cytoplasmic, mitotic apparatus and mixed) were 
prepared. Each algorithm was presented with orientation 
manuals, and the main clinical relevance of the different 
findings have also been addressed.1,2
The III Consensus, conducted in 2007, aimed to upgrade 
the clinical relevance of the test, to suggest effective mea-
sures for quality control, and to evaluate the difficulties in 
implementing the standardization norms.3,4 The definition 
of still controversial aspects of the definition of nucleolus 
positivity was also discussed in III Consensus, and it was 
suggested the incorporation, to the algorithms, of two new 
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fluorescence patterns that remained reserved, so that fur-
ther studies were performed to obtain scientific evidence 
for its recognition – Cytoplasmic Rods/Rings Pattern and 
Speckled Quasi-homogeneous Pattern.3,4 In view of continu-
ing education and of the need to keep up with scientific de-
velopments , the IV Brazilian Consensus for Autoantibodies 
in HEp - 2 cells was held. The event was held in Vitória - 
ES, and gathered 23 experts on the subject from different 
regions of Brazil, and again the difficulties and advances in 
standardization of the test were discussed. The IV Consen-
sus integrated, to the decision tree, the rings/rods pattern, 
the nuclear quasi-homogeneous speckled pattern (QH), and 
the mixed pattern observed with the presence of anti-CENP-
F antibodies. Also was discussed In the Consensus the need 
for attention to the classification of mixed nuclear pattern 
associated with the presence of anti-DNA topoisomerase 
antibodies.9 Guidelines for quality control for the test and 
for the screening and exhaustion dilutions were suggested. 
Finally, warnings were issued about the heterogeneity of 
substrates available on the market and about the use of au-
tomated methodologies for detection of autoantibodies.
The results of the IV Consensus allowed further progress 
in improving the criteria that enable the satisfactory control 
and utilization of the potentiality of this auxiliary method 
of diagnosis.
Work methodology
During the XXIX Brazilian Congress of Rheumatology (BCR), 
23 researchers and experts from universities and private 
laboratories in different regions of Brazil took part in the 
IV Consensus in Vitória (ES), on September 18, 2012. In this 
event, recommendations related to technical procedures, 
standardization in the implementation and interpretation of 
test results were discussed and approved. Commercial rep-
resentatives of different manufacturing companies attended 
the meeting as listeners, without commenting, voting, or 
presentation rights. Different topics related to the descrip-
tion of new patterns, the technical procedure of the test, the 
dilution and titration of sera, the reproducibility of differ-
ent brands of substrates, the use of automated methods for 
identifying autoantibodies, and presentation of reports were 
discussed. Each of the topics was presented to members of 
the assembly by relators and discussed widely, in order to 
establish recommendations. Each relator was based on data 
from the literature and from the presentation of personal 
studies.
 General recommendations
I- Cytoplasmic rods/rings pattern
The rods/rings pattern was presented during the III Consen-
sus, although at that time without defined immunological 
identity and only with preliminary scientific evidence. There-
fore, this pattern was not incorporated into the decision tree 
at that occasion, with the recommendation of additional 
studies. After these studies, inosine monophosphate dehy-
drogenase 2 (IMPDH2) and cytidine triphosphate synthase 1 
(CTPS1) were recognized as antigenic targets.10 These are es-
sential enzymes in the biosynthesis of cytidine triphosphate 
and guanosine triphosphate, respectively. CTP is involved in 
the biosynthesis of nucleic acids (DNA, RNA) and phospholip-
ids, with an important role in cell proliferation.11 IMPDH2 cat-
alyzes the NAD-dependent oxidation of inosine monophos-
phate to xanthosine monophosphate, an essential process in 
the biosynthesis of guanosine monophosphate – therefore, an 
activity also closely related to the cell proliferation mecha-
nism.12 From the pharmacological inhibition of CTPS1 (6-di-
azo-5-oxo-L-norleucine [Acivicin]) and IMPDH2 (Ribavirin), a 
dose-dependent induction of cytoplasmic rods/rings struc-
tures on substrates of neoplastic cells, including HEp-2 cells, 
was evidenced.10
The Keppeke et al. (2012) study confirmed the close as-
sociation between cytoplasmic rods/rings pattern and HCV 
infection. In a sample of 597 subjects with several clinical 
conditions, antibodies associated with the rods/rings pat-
tern occurred exclusively in patients with HCV. Among 342 
patients with HCV, the autoantibody occurred in 38% of those 
treated with ribavirin and interferon alpha, but in none of the 
other patients, including those receiving one of these drugs as 
monotherapy. Demographic parameters, time since diagno-
sis, response to treatment, virus genotype or viral load were 
not correlated with the pattern.13 In the study by Covini et al. 
(2012), the production of autoantibodies against cytoplasmic 
structures after treatment with Ribavirin/IFN was observed in 
15 HCV-positive participants.14
The IV Consensus integrated the rods/rings pattern to the 
decision tree (Fig. 1); this pattern was classified as an inde-
pendent Cytoplasmic Pattern, not entailed to other cytoplas-
mic patterns. A relevant information on the characterization 
of this pattern was related to the fact that the rods/rings 
structures are not expressed in all commercial substrates.15 
Therefore, the IV Consensus suggested that, in the report, be 
informed that the recognition of this pattern is dependent on 
substrate.
II - Quasi-homogeneous speckled pattern (QH)
The IV Consensus integrated the nuclear quasi-homoge-
neous speckled (QH) pattern into the nuclear pattern deci-
sion-making tree. This pattern fits into the interpretation 
guide as optional (Fig. 1) and is characterized by extremely 
thin specked nuclear fluorescence, approaching the homo-
geneous texture, with the metaphase plate similarly stained. 
This is a pattern distinct of the nuclear homogeneous and of 
the nuclear dense fine speckled patterns, where a single an-
tigenic specificity is not noted, but miscellaneous antigenic 
targets are recognized. França et al. showed that the quasi-
homogeneous fine speckled pattern exhibits a autoantibody 
profile intermediate between that of the dense fine speck-
led pattern and the homogeneous pattern. Also, the clinical 
profile associated with quasi-homogeneous fine speckled 
pattern lies in a gray area between the dense fine speckled 
pattern and the homogeneous pattern.16 Therefore, the iden-
tification of this pattern suggests further investigation of the 
clinical diagnosis, because it can be related to systemic auto-
immune rheumatic diseases.17
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III – Mixed pattern of CENP-F type
The IV Consensus integrated the CENP-F pattern into the 
mixed pattern decision tree. This pattern is characterized by 
thin specked fl uorescence of variable intensity in the nuclear 
matrix in interphase cells and with nucleoli usually negative. 
In this pattern a delicate lacy decoration of kinetochores is 
noted, being predominantly visible in prophase and meta-
phase. The mitotic apparatus still exhibits occasional punc-
tual markings in the central region of the intercellular bridge, 
in telophase cells. Finally, the fi gures in prophase exhibit deli-
cate coloration of the nuclear envelope.18
This is a complex pattern, caused by antibodies against a 
350 kDa protein, known as CENP-F or mitosin. This protein 
plays an important role in the organization of cytoplasmic 
microtubules, methylation of histone H3, regulation of some 
transcription factors and cell cycle progression to mitosis.19,20 
Rattner et al. identifi ed the serum pattern from a patient with 
lung cancer18 and later in breast cancer.21.22 Cassiano et al. re-
ported positivity for the pattern in different neoplastic dis-
eases, chronic liver diseases, chronic renal allograft rejection 
and Crohn's disease.23 The presence of the CENP-F pattern in 
a patient with colorectal carcinoma has been reported.24 As 
a whole, the literature points to the suspicion of neoplastic 
disease in patients with this pattern.
IV - Mixed pattern of anti-DNA topoisomerase type
The IV Consensus drew attention to the compound pattern 
related to the presence of anti-DNA topoisomerase I (Scl-70). 
Fig. 1 – Classifi cation trees for nuclear, nucleolar, cytoplasmic, of the mitotic apparatus and mixed patterns. The arrows 
indicate the additions of new recognized patterns.
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In the literature, the classic description of the pattern associ-
ated with anti-DNA topoisomerase I antibodies is restricted to 
the nucleus and nucleolus, with no specificity in this finding. 
It was recently shown that anti-DNA topoisomerase I anti-
bodies cause an extremely specific pattern, characterized by 
decoration of five cellular domains, namely, nucleus, nucleo-
lus, cytoplasm, nucleolus organizer region and metaphase 
plate chromosomes.9
V - Titration of the conjugate and quality control of the assay
The IV Consensus stressed again the need for a rigorous qual-
ity control of the assay in order to restrict false-positive reac-
tions in non- autoimmune individuals, but with request for 
the test and with the purpose of minimizing the differences 
of results between different laboratories. The continued need 
for titration of the conjugate for equalization of Brazilian 
laboratories’ systems and the use of adjacent negative and 
positive controls was recommended. This orientation, previ-
ously established and detailed in III Consensus,4 underscores 
the need for the Brazilian laboratories ensure the quality of 
the test. In this sense, it must be emphasized the need for 
specific training and qualification of technical staff, in addi-
tion to considering the heterogeneity of commercial kits and 
of optical equipment between different services. The need of 
performing the titration of the conjugate for each new batch 
of commercial kit was reinforced, based on the use of com-
mercial reference sera, or of sera coming from other services.4 
Considering that the investigation of autoantibodies on 
HEp-2 cells depends technically on multiple factors (micro-
scope power lamp ranging from 20, 50 or 100 W; concentration 
and protein/fluorescein rate of the conjugate; minimal reac-
tivity of control sera in dilution 1/80; qualification and inher-
ent subjectivity of the observer), it appears that the titration 
of the conjugate is a fundamental parameter and subject to 
adjustment, in order to ensure the recognition of the nominal 
title of control sera. This measure is considered vital, in order 
to achieve objectivity and accuracy for the method.4
VI – Screening dilution and titration of sera
The IV Consensus urged the Brazilian laboratories the use of 
a screening dilution of 1 /80. This recommendation is based 
on the fact that some autoimmune patients may have titles 
of 1/80, although most of them present moderate (1/160 and 
1/320) to high (≥ 1/640) autoantibody titles on HEp - 2 cells, 
while healthy subjects tend to have low titers (1/40 and 
1/80).17,25 Another aspect which reinforced the need for this 
recommendation was the fact that the test continues to be 
requested by a variety of specialists that attend patients from 
various types in services, where the autoimmune rheumatic 
diseases are less prevalent. The IV Consensus emphasizes 
that the test should be requested in the presence of a com-
pelling clinical suspicion of autoimmune disease, preventing 
that the request of the test in an inappropriate clinical con-
text (low pretest probability) result in confusion in the clinical 
reasoning.4
Another orientation was related to depletion of serum up 
to 1/640: the positive samples can be released as ≥ 640, for it 
has been shown that up to this title there is substantial gain 
in terms of positive predictive value for the diagnosis of auto-
immune rheumatic diseases.17,26 In some circumstances, the 
continuity of dilution for discriminating one (or more than 
one) concurrent pattern may be desirable. 
VII-Reproducibility of different patterns
The IV Consensus warned about the reproducibility of differ-
ent patterns among different commercial brands. There is a 
degree of variation among different commercial substrates 
available in the Brazilian market, and this variability can af-
fect differently the definition of different patterns. The vari-
ations may be related to the batches, being inherent to the 
manufacturing process of the kits.
In a recent study, Dellavance et al. (2013 ) analyzed 17 pat-
terns of recognized diagnostic relevance in eight substrates. 
The processing of reactions and the reading were done 
blindly and independently by three diagnostic centers. Gen-
erally a good reproducibility of the 17 tested patterns was 
evidenced.27 However, some patterns showed significant vari-
ability of recognition in some commercial substrates, such as 
the CENP-F pattern, the cytoplasmic fine speckled (associated 
with anti-Jo-1) pattern, and the nuclear speckled pattern type 
PCNA pleomorphic. Such patterns have been recognized in 
only two of the eight tested substrates.27 This study showed 
that the most part of the patterns was adequately recognized 
in most antigenic substrates analyzed. Possibly one of the as-
pects that subsidized this high rate of reproducibility was the 
fact that the samples used in the study were immunologically 
and morphologically well characterized. These results cannot 
be extrapolated to the situation of samples with fluorescence 
patterns less well characterized.
Considering that autoimmune patients do not always 
present monospecific sera, IV Consensus warned to the need 
to use a panel of control samples for validation of batches 
and commercial brands of HEp-2 cells used in laboratories, 
because this measure will ensure greater reliability and safety 
in the application of the results by clinicians. Furthermore, 
the use of more than one commercial brand of substrate for 
specific cases is recommended, and that, for each new batch 
or slide brand, the reference sera, representing the different 
cellular regions and patterns, be tested.
VIII - Automated methods for autoantibodies screening 
The IV Consensus does not recommend the use of automated 
assays (EIA and chemiluminescence) in the screening of au-
toantibodies. There is considerable supply of commercial kits 
for screening of autoantibodies based in solid phase immuno-
assays and with antigenically distinct formulations. Despite 
the considerable progress of the industry in improving these 
products, its diagnostic performance do not superpose on the 
traditional indirect immunofluorescence assay with HEp-2 
cells. False-negatives in ANA ELISA, for example, can create 
serious diagnostic problems, with unsuspected consequenc-
es.28,29 In addition, that test allows the preliminary analysis 
of the likely autoantibodies present in a certain serum, with 
careful interpretation of the immunofluorescence pattern, 
while the solid phase immunoassays only provide a numeri-
cal result.
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IX - Detection of specifi c antibodies
The IV Consensus alert to the choice of methods for identi-
fi cation of specifi c autoantibodies such as anti-native DNA 
antibodies and antibodies against extractable nuclear anti-
gens. The Consensus emphasizes the need to take care for 
the excessive sensitivity of the immunoenzymatic methods, 
given that the standardization of the detection of specifi c au-
toantibodies and their clinical correlations were originally de-
scribed based on the method of double immunodiffusion and 
its counterpart, counterimmunoelectrophoresis.
Automated methods are more sensitive, and its positive 
predictive value is generally lower, being therefore suitable 
for carrying screening services in general, but not in special-
ized laboratories. For the other hand, the double immunodif-
fusion is a method that ensures excellent clinical correla-
tion, being relevant as a confi rmatory test when automated 
methods are used in a fi rst phase, or as method of choice for 
supportive laboratories for rheumatology. The use of more 
sensitive methods tends to produce positive results in clini-
cal contexts different than those in which autoantibodies are 
expected, and this may impair the diagnostic process. Ulti-
mately, it is possible that the widespread use of ultrasensitive 
methods compromise the reputation of these autoantibodies 
as specifi c biomarkers.
With the use of solid phase immunoassays, it was recom-
mended that the results be confi rmed by specifi c methods 
(double immunodiffusion, counterimmunoelectrophoresis, 
Crithidia luciliae immunofl uorescence, immunoblotting, etc.), 
to ensure high specifi city to the fi nal result. This recom-
mendation is essential in defi ning the diagnosis, being less 
relevant in monitoring the patient. Therefore, the choice of 
method of identifi cation must be deployed with care, based 
on the profi le of patients attending the service.
X- The report
The IV Consensus kept the presentation of the results descrip-
tively, but suggested that the report is presented at the top of 
the result, making the presentation easier to the Rheumatolo-
gist (Fig. 2). It was recommended that the report continues 
to contemplate the reactivity (fl uorescent/non-fl uorescent, 
or reactive/non-reactive) in different cellular compartments 
(nucleus, nucleolus, cytoplasm, mitotic apparatus), singly or 
in combination (in the case of mixed patterns). 
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